Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Clinical Characteristics and Outcomes of TFE3-Rearranged/TFEB-Altered Renal Cell Carcinoma with Systemic Therapies, Including Tyrosine Kinase Inhibitors or Immune Checkpoint Inhibitors: An Observational Study

Purpose TFE3-rearranged/TFEB-altered renal cell carcinoma (RCC) is a rare subtype of RCC. Due to its rarity, there is an unmet medical need for effective therapies in advanced settings. The study aims to investigate the clinical and histopathological characteristics of patients with microphthalmia t...

Podrobná bibliografie
Hlavní autoři:	Joohyun Hong, Ghee Young Kwon, Minyong Kang, Seong Il Seo, Se Hoon Park
Médium:	Článek
Jazyk:	English
Vydáno:	Korean Urological Oncology Society 2024-03-01
Edice:	Journal of Urologic Oncology
Témata:	-rearranged -altered renal cell carcinoma tyrosine kinase inhibitors immune checkpoint inhibitors
On-line přístup:	http://www.e-juo.org/upload/pdf/juo-234600660033.pdf

Podobné jednotky

Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma
Autor: Huang JT, a další
Vydáno: (2022-11-01)

Safety and Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma: A Single Center Experience
Autor: Pan X, a další
Vydáno: (2023-06-01)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
Autor: Fei Yang, a další
Vydáno: (2022-01-01)

Immune checkpoint inhibitor plus tyrosine kinase inhibitor with or without transarterial chemoembolization for unresectable hepatocellular carcinoma
Autor: Hongyu Pan, a další
Vydáno: (2025-03-01)

Efficacy of the immune checkpoint inhibitor nivolumab in the treatment of advanced hepatocellular carcinoma with the exhausted possibilities of therapy with tyrosine kinase inhibitors
Autor: A. Yu. Goryainova, a další
Vydáno: (2021-12-01)

Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
Autor: Gao B, a další
Vydáno: (2023-12-01)

Prognostic significance of psoas muscle index in male hepatocellular carcinoma patients treated with immune checkpoint inhibitors and tyrosine kinase inhibitors
Autor: Ning Luo, a další
Vydáno: (2023-08-01)

Additive toxicity arising from combined use of immune checkpoint inhibitors and tyrosine kinase inhibitors in patients with renal or endometrial carcinoma: Protocol for a rapid systematic review
Autor: Shannon E. Kelly, a další
Vydáno: (2024-06-01)

Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study
Autor: Guosheng Yuan, a další
Vydáno: (2024-03-01)

Second-Line Treatment after Failure of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Tyrosine Kinase Inhibitor, Retrial of Immunotherapy, or Locoregional Therapy?
Autor: Sang Youn Hwang, a další
Vydáno: (2023-11-01)

Salvage lenvatinib/everolimus combination therapy after immune checkpoint inhibitor and VEGFR tyrosine kinase inhibitor for metastatic renal cell carcinoma
Autor: Christopher Kwok, a další
Vydáno: (2023-07-01)

Enhanced efficacy of immune checkpoint inhibitors combined locoregional therapy and tyrosine kinase inhibitors in the treatment of unresectable hepatocellular carcinoma: A single - center retrospective study
Autor: Junfeng Bu, a další
Vydáno: (2025-02-01)

Obesity, Sarcopenia, and Outcomes in Non-Small Cell Lung Cancer Patients Treated With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors
Autor: Karam Khaddour, a další
Vydáno: (2020-10-01)

Prognostic value of platelet-to-lymphocyte ratio in patients with unresectable hepatocellular carcinoma undergoing transarterial chemoembolization and tyrosine kinase inhibitors plus immune checkpoints inhibitors
Autor: Yiwan Guo, a další
Vydáno: (2024-01-01)

Toxicity of immune checkpoint inhibitors and tyrosine kinase inhibitor combinations in solid tumours: a systematic review and meta-analysis
Autor: David O’Reilly, a další
Vydáno: (2024-07-01)

Advances in MET tyrosine kinase inhibitors in gastric cancer
Autor: Yifan Zhang, a další
Vydáno: (2024-06-01)

Prognostic value of the neutrophil-to-lymphocyte ratio and prognostic nutritional index in unresectable hepatocellular carcinoma patients treated with tyrosine kinase inhibitors and immune checkpoint inhibitors
Autor: Shasha Sun, a další
Vydáno: (2024-12-01)

Enhancing the Potential of Immunotherapy in Paediatric Sarcomas: Breaking the Immunosuppressive Barrier with Receptor Tyrosine Kinase Inhibitors
Autor: Emmy D. G. Fleuren, a další
Vydáno: (2021-11-01)

Newly emerged ROS1 rearrangement in a patient with lung adenocarcinoma following resistance to immune checkpoint inhibitors: a case report
Autor: Jian Wang, a další
Vydáno: (2024-12-01)

Interventional therapy combined with tyrosine kinase inhibitors with or without immune checkpoint inhibitors as initial treatment for hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis
Autor: Changjie Du, a další
Vydáno: (2024-05-01)

A preliminary study on drug switching strategy for second-line therapy after combination treatment of tyrosine kinase inhibitors and immune checkpoint inhibitors for unresectable hepatocellular carcinoma
Autor: Renguo Guan, a další
Vydáno: (2022-09-01)

Lenvatinib and immune-checkpoint inhibitors in hepatocellular carcinoma: mechanistic insights, clinical efficacy, and future perspectives
Autor: Yuhang Chen, a další
Vydáno: (2024-12-01)

The Significance of Transarterial Chemo(Embolization) Combined With Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors for Unresectable Hepatocellular Carcinoma in the Era of Systemic Therapy: A Systematic Review
Autor: Qiao Ke, a další
Vydáno: (2022-05-01)

Targeting ALK Rearrangements in NSCLC: Current State of the Art
Autor: Ling Peng, a další
Vydáno: (2022-04-01)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
Autor: Yue Chen, a další
Vydáno: (2022-06-01)

Inhibitory effects of regorafenib, a multiple tyrosine kinase inhibitor, on corneal neovascularization
Autor: Halil Ibrahim Onder, a další
Vydáno: (2014-04-01)

Best practices in the management of thyroid dysfunction induced by immune checkpoint inhibitors
Autor: Ichiro Yamauchi, a další
Vydáno: (2025-01-01)

Inhibition of hyperprogressive cancer disease induced by immune-checkpoint blockade upon co-treatment with meta-tyrosine and p38 pathway inhibitor
Autor: Daniela R. Montagna, a další
Vydáno: (2022-08-01)

Peptide and peptide-inspired checkpoint inhibitors: Protein fragments to cancer immunotherapy
Autor: Pottayil G. Sasikumar, a další
Vydáno: (2020-12-01)

Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors
Autor: Ryo Ariyasu, MD, a další
Vydáno: (2023-06-01)

Mechanisms of acquired resistance to tyrosine kinase inhibitors
Autor: Yi-fan Chen, a další
Vydáno: (2011-12-01)

A deep learning-based system for survival benefit prediction of tyrosine kinase inhibitors and immune checkpoint inhibitors in stage IV non-small cell lung cancer patients: A multicenter, prognostic study
Autor: Kexue Deng, a další
Vydáno: (2022-09-01)

Cabozantinib in combination with immune checkpoint inhibitors for renal cell carcinoma: a systematic review and meta-analysis
Autor: Jingyang Su, a další
Vydáno: (2024-04-01)

Calcineurin inhibitors in steroid and anti‐TNF‐alpha refractory immune checkpoint inhibitor colitis
Autor: Eva Zhang, a další
Vydáno: (2021-05-01)

Recent Advances in Immune Checkpoint Inhibitor-associated Pneumonitis
Autor: CHEN Shuangqing, a další
Vydáno: (2022-10-01)

A Lung Cancer Patient Harboring a Rare Oncogenic EGFR Exon 20 V786M Mutation Responded to a Third-Generation Tyrosine Kinase Inhibitor: Case Report and Review of the Literature
Autor: Qi Zhu, a další
Vydáno: (2022-05-01)

Clinical diagnosis and treatment of immune checkpoint inhibitor‐associated pneumonitis
Autor: Hanping Wang, a další
Vydáno: (2020-01-01)

Combining immune checkpoint inhibition plus tyrosine kinase inhibition as first and subsequent treatments for metastatic renal cell carcinoma
Autor: Yuanquan Yang, a další
Vydáno: (2022-08-01)

Fatal Case of Immune-Related Myocarditis and Myositis Due to Treatment with Immune Checkpoint and Tyrosine Kinase Inhibitors
Autor: João Queirós Coelho, a další
Vydáno: (2024-10-01)

Targeting tumour microenvironment by tyrosine kinase inhibitor
Autor: Hor-Yue Tan, a další
Vydáno: (2018-02-01)